ArticleDiabetes, obesity & metabolism2026
Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve metabolic control while preventing advanced liver outcomes are limited.
aimsTo evaluate the association between semaglutide treatment and the risk of liver cirrhosis and hepatocellular carcinoma in adults with type 2 diabetes mellitus.
methodsWe performed a retrospective population-based cohort study using electronic health records from a large integrated healthcare organization. Adults with type 2 diabetes mellitus and no prior diagnosis of liver cirrhosis or hepatocellular carcinoma were included. Exposure was defined as treatment with semaglutide for at least four consecutive months compared with matched control patients. Cox proportional hazards models estimated adjusted hazard ratios with 95% confidence intervals, accounting for demographic factors, body mass index, smoking status, glycaemic control, other antidiabetic treatments and baseline liver fibrosis risk.
resultsAmong 71 612 individuals, 35 806 received semaglutide and 35 806 were matched controls. Over a median follow-up of 4628 days for liver cirrhosis and 4090 days for HCC, 245 patients developed liver cirrhosis and 21 developed hepatocellular carcinomas. In the Cox model, there was no association between semaglutide treatment and the diagnosis of liver cirrhosis (HR 1.3, 95% CI 0.98-1.77) or hepatocellular carcinoma (HR 0.6, 95% CI 0.21-1.51).
conclusionsIn this real-world study, semaglutide treatment was not associated with a reduced risk of liver cirrhosis or hepatocellular carcinoma among adults with type 2 diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.